Sulfadoxine pyrimethamine + Pyramax
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria in Pregnancy
Conditions
Malaria in Pregnancy
Trial Timeline
May 6, 2021 → Jun 22, 2022
NCT ID
NCT04783051About Sulfadoxine pyrimethamine + Pyramax
Sulfadoxine pyrimethamine + Pyramax is a phase 3 stage product being developed by Novartis for Malaria in Pregnancy. The current trial status is completed. This product is registered under clinical trial identifier NCT04783051. Target conditions include Malaria in Pregnancy.
What happened to similar drugs?
11 of 18 similar drugs in Malaria in Pregnancy were approved
Approved (11) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04783051 | Phase 3 | Completed |
Competing Products
20 competing products in Malaria in Pregnancy